Health
Russia’s COVID-19 vaccine shows over 91% efficacy in phase 3 trial: Lancet study – The Tribune India
Findings based on analysis of data from nearly 20,000 participants; Sputnik V is a two-part vaccine that includes two adenovirus vectors
Moscow, February 2
Russia’s Sputnik V vaccine against COVID-19 has shown 91.6 per cent efficacy in the phase 3 trial without any serious side effects, according to an interim analysis of data published in The Lancet journal on Tuesday.
The findings are based on analysis of data from nearly 20,000 participants – three-quarters of whom received the two-dose regimen of the adenovirus-based vaccine, Gam-COVID-Vac, and one quarter received a placebo.
Serious adverse events or those requiring hospital…
-
Noosa News15 hours agoFlatmates of missing teen Pheobe Bishop, 17, identified
-
Noosa News17 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
General14 hours agoPostecoglou’s message touches Blues AFL coach Voss after Spurs’ Europa League win
-
General21 hours agoOne person dead after house fire in Melbourne’s south-east